Agios Pharmaceuticals, Inc.
AGIO
$34.41
-$1.09-3.07%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 25.96% | 36.07% | 36.79% | 55.39% | 54.61% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 25.96% | 36.07% | 36.79% | 55.39% | 54.61% |
| Cost of Revenue | 3.41% | 2.36% | 2.89% | 12.64% | 7.45% |
| Gross Profit | -0.96% | 0.97% | 0.16% | -9.25% | -4.00% |
| SG&A Expenses | 36.51% | 30.76% | 19.62% | 5.81% | 3.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.02% | 10.50% | 7.70% | 10.55% | 6.24% |
| Operating Income | -12.05% | -8.75% | -5.88% | -8.14% | -3.81% |
| Income Before Tax | 301.42% | 303.92% | 431.22% | -73.74% | -61.72% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 288.87% | 291.35% | 407.03% | -73.74% | -61.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 288.87% | 291.35% | 407.03% | -73.74% | -61.72% |
| EBIT | -12.05% | -8.75% | -5.88% | -8.14% | -3.81% |
| EBITDA | -12.40% | -9.15% | -6.34% | -8.69% | -4.35% |
| EPS Basic | 285.73% | 286.86% | 398.96% | -70.84% | -58.94% |
| Normalized Basic EPS | -5.29% | -3.26% | -2.85% | -6.78% | -0.95% |
| EPS Diluted | 278.75% | 279.89% | 387.77% | -71.03% | -58.94% |
| Normalized Diluted EPS | -4.66% | -2.64% | -2.21% | -6.78% | -0.95% |
| Average Basic Shares Outstanding | 2.05% | 2.08% | 2.00% | 1.92% | 1.75% |
| Average Diluted Shares Outstanding | 2.72% | 2.75% | 2.67% | 1.92% | 1.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |